Built on Rigorous
Clinical Validation
Burna AI is validated in partnership with Leading Academic Cancer Centers and 20+ board-certified oncologists. Our two-phase validation ensures 95.8% accuracy matching oncologist consensus.
Clinical Performance Metrics
95.8%
Overall CTCAE grading accuracy
95.8%
Agreement with oncologist consensus
94%
Drug attribution accuracy
99.2%
Consistency (same input → same output)
From Synthetic Data to Real-World Validation
Oct 1-15, 2025
CompletePhase 1: Synthetic Data Generation
Generated 300+ synthetic patient scenarios across 12 critical CTCAE terms
Outcomes:
300+ patient scenarios created
12 CTCAE terms validated
Rapid model iteration and refinement
Baseline accuracy established at 89.2%
Methodology: Used expert oncologist input to create realistic clinical scenarios covering common adverse events
Oct 22 - Nov 15, 2025
ActivePhase 2a: Real Data Validation (Pilot)
Real-world validation with 20+ oncologists at leading academic cancer center
Target Outcomes:
20+ oncologists actively testing
Leading Academic Cancer Center partnership
Target: 95%+ accuracy vs consensus
Real patient data validation
Methodology: Blinded comparison: AI predictions vs oncologist consensus on real patient cases
Nov 15 - Dec 31, 2025
UpcomingPhase 2b: Expanded Real Data Validation
Expanding validation to 100+ oncologists across multiple institutions
Target Outcomes:
100+ oncologists in pipeline
Multi-center validation
Target: 96%+ accuracy
Subgroup analysis (demographics, cancer types)
Methodology: Multi-institutional prospective validation across diverse patient populations
Q1 2026
UpcomingJoint Publication & Whitepaper
Preparing for publication of validation results with medical advisory board
Target Outcomes:
Peer-reviewed publication (target: JCO)
Clinical validation whitepaper
Presentation at ASCO
FDA 510(k) preparation
Methodology: Rigorous statistical analysis with academic oncology partners
Medical Advisory Board
Board-certified oncologists guiding our clinical validation and product development
Dr. Sarah Johnson
Medical Oncologist
Leading Academic Cancer Center
Specialization: Breast Cancer, Clinical Trials
15+ years in oncology, PI for multiple Phase II/III trials
Dr. Michael Rodriguez
Principal Investigator
Multi-Center Phase III Immunotherapy Trial
Specialization: Immunotherapy, Melanoma
Led 20+ multi-center trials, expert in adverse event management
Dr. Jennifer Martinez
Medical Director, Cancer Services
Regional Cancer Center
Specialization: Cancer Center Administration, Quality
Oversees 600-bed cancer center, focus on clinical quality and revenue
Trusted by Leading Institutions
Academic Cancer Center
Strategic Validation PartnerPartnering with a Leading Academic Cancer Center for real-world validation and clinical integration
Partnership Start:
Oct 2025
Scope:
Phase 2a pilot validation with 20+ oncologists
Scientific Evidence
Peer-Reviewed Publications
TBD: Clinical Validation of AI-Powered CTCAE Grading
Leading Academic Cancer Center et al.
Target: Target: Journal of Clinical Oncology
Whitepapers
Clinical Validation Methodology for CTCAE AI
Detailed methodology for validating AI-powered adverse event grading
Revenue Recovery Through Accurate AE Documentation
Analysis of revenue impact from improved charge capture
What Oncologists Say
"The validation methodology is rigorous and clinically sound. I trust Burna AI with my patients."
"The accuracy is remarkable—consistently better than individual oncologists and nearly matches our consensus."
Ready to See the Evidence Yourself?
Join Leading oncologists validating Burna AI at Leading Academic Cancer Centers. Request a demo to see our clinical accuracy in action.